Lancet review finds strong evidence for CBD in severe epilepsy but not for other neurological disorders
A Lancet Neurology review found robust RCT evidence supporting CBD for Lennox-Gastaut and Dravet syndromes, approved treatments for MS pain and spasticity, but no effect found in trials for Huntington's, ADHD, or dementia.
Quick Facts
What This Study Found
Randomized controlled trials provide evidence of CBD's anti-seizure effects for Lennox-Gastaut and Dravet syndromes. Cannabis-based treatments for MS pain and spasticity are approved in some countries. However, small clinical trials found no effects for Huntington's disease, ADHD, or dementia.
Key Numbers
CBD approved for Lennox-Gastaut and Dravet syndromes based on RCTs. Cannabis-based treatments for MS pain and spasticity approved in some countries. No effect found in small trials for Huntington's disease, ADHD, and dementia.
How They Did This
Narrative review published in The Lancet Neurology examining the evidence for cannabinoids across neurological disorders including epilepsy, multiple sclerosis, pain, and neurodegenerative diseases, focusing on randomized controlled trial data.
Why This Research Matters
Published in a top-tier neurology journal, this review provides a reality check on cannabinoid therapeutics. While epilepsy and MS have genuine evidence, the enthusiasm around cannabis for neurological conditions generally outpaces the science.
The Bigger Picture
The pattern is clear: where large, well-designed RCTs have been conducted (severe pediatric epilepsy), CBD shows real benefit. Where only small trials exist (ADHD, dementia), no effects have been found. This suggests the field needs more rigorous trials, not more anecdotes.
What This Study Doesn't Tell Us
Narrative review format. Negative findings for conditions like ADHD and dementia may reflect underpowered studies rather than true absence of effect. Mechanisms of cannabinoid action remain incompletely understood.
Questions This Raises
- ?Could larger, better-designed trials find cannabinoid effects in ADHD or dementia?
- ?Do CBD's anti-seizure effects extend beyond Dravet and Lennox-Gastaut to other epilepsies?
- ?What are the long-term effects of cannabinoid treatments for neurological conditions?
Trust & Context
- Key Stat:
- Strong evidence for epilepsy and MS; no effect found for Huntington's, ADHD, or dementia
- Evidence Grade:
- Strong: published in The Lancet Neurology, synthesizing RCT evidence across multiple neurological conditions.
- Study Age:
- Published in 2019.
- Original Title:
- Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders.
- Published In:
- The Lancet. Neurology, 18(5), 504-512 (2019)
- Authors:
- Friedman, Daniel(3), French, Jacqueline A, Maccarrone, Mauro(19)
- Database ID:
- RTHC-02041
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Which neurological conditions does cannabis actually help?
Based on RCT evidence reviewed here, CBD helps severe childhood epilepsies (Dravet and Lennox-Gastaut syndromes), and cannabis-based treatments have been approved for MS pain and spasticity in some countries. No benefit was found for Huntington's, ADHD, or dementia.
Why doesn't cannabis work for all brain conditions?
The endocannabinoid system interacts differently with different neurological pathways. Just because cannabinoids affect the brain doesn't mean they help every brain disorder. The evidence so far shows targeted benefits, not broad-spectrum neurological improvement.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-02041APA
Friedman, Daniel; French, Jacqueline A; Maccarrone, Mauro. (2019). Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders.. The Lancet. Neurology, 18(5), 504-512. https://doi.org/10.1016/S1474-4422(19)30032-8
MLA
Friedman, Daniel, et al. "Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders.." The Lancet. Neurology, 2019. https://doi.org/10.1016/S1474-4422(19)30032-8
RethinkTHC
RethinkTHC Research Database. "Safety, efficacy, and mechanisms of action of cannabinoids i..." RTHC-02041. Retrieved from https://rethinkthc.com/research/friedman-2019-safety-efficacy-and-mechanisms
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.